Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
Various forms of human muscular dystrophy result from mutations in genes encoding proteins of the nuclear envelope. A new paper in the February 15th issue of G&D reveals how.
Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids (RNA).
...according to research published today in Physical Review Letters, "Dynamics and Spatial Organization of Endosomes in Mammalian Cells."
In mice, that had been genetically engineered to develop Alzheimer's disease, scientists were able to reverse the rodents' memory loss by reducing the amount of an enzyme that is crucial for the development of Alzheimer's disease.
Intradigm Corporation announced today its collaboration with Chinese academic and biotech groups has achieved clear evidence of prophylactic and therapeutic effects of siRNA (small interfering RNA) agents in Rhesus monkey to treat SARS coronavirus (SCV) respiratory infection.
...has begun at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Working within the MitoCheck consortium that includes 10 other institutes throughout Europe, the EMBL scientists will silence all human genes, one-by-one, to find those involved in cell division (mitosis) and to answer fundamental questions of how cell division is regulated.
Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).
For the first time, scientists have shown that humans use an immune defense process common in plants and invertebrates to battle a virus.
Researchers at the University of Dundee have identified a way of inactivating a naturally occurring human protein, a development which could offer new routes to developing cancer prevention treatments.
Sirna Therapeutics announced today that its collaborator at the University of Iowa, Dr. Beverly Davidson, published groundbreaking results for the potential treatment of Huntington's Disease (HD).
Researchers at Penn State College of Medicine have identified the mechanism by which the most mutated gene in melanoma, called v599EB-Raf, aids melanoma tumor development demonstrating its importance as a therapeutic target.
Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.
The protein, Akt3, appears to be responsible for promoting tumor cell survival and development in 43 percent to 60 percent of non-inherited melanomas.
Ever since the approval of Gleevec in 2001, a cancer-cell-specific drug used to treat chronic myelogenous leukemia (CML), the field of cancer therapeutics has been rushing full speed into the era of so-called "targeted" medicines.
Sirna Therapeutics has announced the publication of preclinical studies evaluating RNA interference-based therapies for a class of inherited neurodegenerative diseases of the central nervous system (CNS) in the current issue of Nature Medicine.
Cyntellect a privately-held biotechnology company, has announced the issuance of U.S. Patent No. 6,753,161 covering the Company's LaserFect(TM) technology.
A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.
Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo and radioresistant mechanisms was by presented by Dr. John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.